RAAS inhibitors lower risk of aneurysm rupture among patients with high blood pressure

Renin-angiotensin-aldosterone system (RAAS) inhibitors can help brain aneurysm patients with high blood pressure reduce their risk of rupture, according to new research published in Hypertension.[1]

The study focused on data from more than 3,000 patients treated at one of 20 different facilities in China from 2016 to 2021. The average patient age was 61 years old.

Overall, 32% of patients taking RAAS inhibitors and 67% of patients not taking RAAS inhibitors experienced an intracranial aneurysm rupture. The risk among women was almost double the risk among men.

“We were surprised to find that even among people with controlled hypertension, those who took RAAS inhibitors still had a significantly lower rupture risk than individuals who used non-RAAS inhibitors,” senior author Qinghai Huang, MD, PhD, a professor of neurosurgery with Changhai Hospital in China, said in a statement. “Our study highlights that using the proper antihypertensive medications to achieve normalization of blood pressure may remarkably decrease the risk of a ruptured aneurysm.”

The researchers also noted that uncontrolled hypertension, exposure to second-hand smoke and untreated type 2 diabetes were all associated with a greater rupture risk.

“Based on these data, we estimate that nearly 18% of ruptured aneurysms may be prevented if all patients with high blood pressure and intracranial aneurysms were prescribed with RAAS inhibitors,” Huang said in the same statement. “Due to the strong potential benefit and high safety of RAAS inhibitors, these findings may also help clinicians to optimize treatment to help people with high blood pressure prevent aneurysm rupture.”

Related Pharmaceutics Content:

A new use for metformin? Popular type 2 diabetes medication may also improve cancer and infection therapies

Empagliflozin may reverse vascular aging, lower CVD risk

FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

 

Reference:

1. Ping Zhong, Zhiwen Lu, Zhangyu Li, et al. Effect of Renin-Angiotensin-Aldosterone System Inhibitors on the Rupture Risk Among Hypertensive Patients With Intracranial Aneurysms. Hypertension. June 3, 2022.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup